Lercanidipine suffers another setback
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Forest says further development of the calcium channel blocker lercanidipine would require another extended-release formulation, after the current modified-release version failed to meet dose-response criteria in a Phase II study conducted in response to FDA's August 2002 "approvable" letter. Preliminary results of the eight-week, 60-patient efficacy study indicate lercanidipine was "well tolerated" and had a "clinically relevant reduction in blood pressure." Forest says the positive findings warrant further investigation. A new formulation would mean development "would accordingly be somewhat delayed," the company says. Lercanidipine is already three years behind the original launch projection…
You may also be interested in...
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.
Xaira Launches With $1bn-Plus And End-To-End AI Strategy
ARCH and Foresite incubated the company and recruited Genentech R&D veteran Marc Tessier-Lavigne to keep data generation, machine learning research and drug development under one roof.